Peter Visit 2 - A 71-Year-Old Recently Diagnosed with Prostate Cancer

Title:	Peter Visit 2 - A 71-Year-Old Recently Diagnosed with Prostate Cancer
Topic:	Oncology/ Hematology
Relevant Terms:	Cancer, Oncology, Prostate Cancer, Urology
Primary Audience:	Urologists, medical oncologists, radiation oncologists, and healthcare professionals who treat patients with prostate cancer.
Launch Date:	16-Mar-09
Credits:	0.5 AMA PRA Category 1 Credit™
Expiration Date:	The accreditation for this activity has expired.

Enter this activity!

Learning Objectives

After completion of this activity, participants should be able to:

Identify and properly apply diagnostics and treatment modalities available for the management of prostate cancer
Design and assess a plan to effectively use androgen hormone deprivation therapy and radiation therapy in patients with locally advanced prostate cancer

Faculty

Curriculum Leader:
Howard M. Sandler, MD, MS
Chair, Department of Radiation Oncology
Outpatient Cancer Center at Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA

Robert Dreicer, MD
Professor of Medicine, Cleveland Clinic Lerner College of Medicine
Chairman, Department of Solid Tumors
Director of the Genitourinary Medical Oncology Program
Associate Director of Experimental Therapeutics
Taussig Cancer Center, Cleveland Clinic
Cleveland, OH

Robert Dreicer, MD

Robert Dreicer, MD, FACP, is Chairman of the Department of Solid Tumor Oncology at the Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his medical degree from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989 and upon his departure, he was a tenured associate professor of medicine and associate division director of hematology/oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute. He was appointed Director of the Genitourinary Medical Oncology program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January of 2006.

Dr. Dreicer has published widely in genitourinary oncology, and is the principle investigator of a large number of ongoing studies in genitourinary neoplasms. He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians. He is the Chair of the Steering Committee for ASCO’s 2008 GU Oncology Meeting. He is, an Associate Editor of Urology, and a member of the editorial boards of the Journal of Clinical Oncology, the New England Journal of Medicine’s Journal Watch Hematology/Oncology and The Journal Of Supportive Oncology.

DISCLOSURE POLICY STATEMENT It is the policy of ArcMesa Educators that our staff and faculty disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentations. Individuals who refuse to disclose will be disqualified from all aspects of this CME activity. ArcMesa Educators has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

FACULTY DISCLOSURES
Howard M. Sandler, MD, MS has nothing to disclose.
Robert Dreicer, MD has received speaker honorarium from sanofi-aventis, and is a consultant for Astra-Zeneca, Eli Lilly, and Methylgene.

STAFF DISCLOSURE DECLARATIONS The employees of ArcMesa Educators have no financial relationships to disclose.

ACCREDITATION STATEMENT ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION ArcMesa Educators designates this educational activity for a maximum of 0.5 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO RECEIVE CREDIT By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 0.5 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.

Read the learning objectives and faculty disclosures.
Participate in the activity.
Complete the posttest and activity evaluation.
Physicians who successfully complete the posttest and evaluation will receive CME credit. You must score with a 70% or higher on the posttest to receive credit for this activity.
All other participants who successfully complete the posttest and evaluation will receive a certificate of participation.

COURSE VIEWING REQUIREMENTS

PC
Internet Explorer (v6 or greater), or Firefox

MAC
Safari

Release Date: March 16, 2009
Expiration Date: March 31, 2010

ACKNOWLEDGEMENT OF SPONSOR Sponsored by ArcMesa Educators.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT Supported by an educational grant from sanofi-aventis.

DISCLAIMER © 2009 ArcMesa Educators. All rights reserved. None of the contents may be reproduced in any form without prior written permission from ArcMesa Educators.

The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of sanofi-aventis, any other manufacturer of pharmaceuticals or ArcMesa Educators. The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating faculty. Any medications, diagnostic procedures or treatments discussed by the faculty should not be utilized without evaluation of their patient’s conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.

TECHNICAL SUPPORT & CUSTOMER SERVICES
ArcMesa Educators, LLC
Address: 666 Plainsboro Rd, Suite 440, Plainsboro, NJ 08536
Phone: 609-630-6100 | Fax: 609-630-6110 | Email: customer_services@arcmesa.com

Enter this activity!

These activities require registration. Registration time is less than two minutes, and will provide you access to your personal CMECompanion toolset.

If you are already registered, please log in.

(+) What is CMECompanion?